Nexalin Technology, Inc. (NXL) Form 8-K — Oct 1, 2026
Nexalin Technology (Nasdaq: NXL) signed a definitive distribution agreement on September 28, 2026 with Inovanexa Medical Technologies S.A., appointing it exclusive distributor of the Nexalin Sync neurostimulation device across Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador and Venezuela — a territory of more than 300 million people. The agreement carries an initial 10-year term with 10-year renewals, a binding initial order for 10 devices, a 100-device commercialization program, and a Brazil clinical pilot targeted to launch within 90 days.
Key figures
- Countries covered
- 7
- Initial term years
- 10
- Renewal term years
- 10
- Territory population
- 300+ million
- Late payment interest
- 1% per month
- Pilot program launch days
- 90
- Initial committed order devices
- 10
- Local manufacturing trigger devices
- 30
- Clinical trial anxiety response rate
- 77.8%
- Initial commercialization program devices
- 100
- Regulatory transfer revenue threshold usd
- 500000
AI analysis
Red flags7 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.